Search Browse Earnings

BridgeBio Pharma, Inc. — SlamSEC

BridgeBio Pharma, Inc.

Nasdaq:BBIO

Pharmaceutical Preparations·PALO ALTO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$9.3M

-88.0% YoY

FY 2025

Adj. EBITDA

-$600.9M

-6458.9% margin

FY 2025

Net Income

—

EPS (Diluted)

-$3.95

FY 2025

Stock Price

$68.00

-8.6%

2026-03-12

52W Range

$28.32 – $84.94

P/E Ratio

-17.2x

Market Cap

$13.2B

Cash

$375.9M

FY 2025

Total Debt

$446.4M

FY 2024

Net Debt

$70.5M

FY 2024

Enterprise Value

$13.3B

Debt / EBITDA

-0.1x

FY 2025

EV / EBITDA

-22.1x

Employees

—

CEO

Kumar Neil

CFO

Trimarchi Thomas